- Home
- FMNB vs RGNX Comparison
FMNB vs RGNX Comparison
Compare FMNB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMNB
- RGNX
- Stock Information
- Founded
- FMNB 1887
- RGNX 2008
- Country
- FMNB United States
- RGNX United States
- Employees
- FMNB N/A
- RGNX N/A
- Industry
- FMNB Major Banks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMNB Finance
- RGNX Health Care
- Exchange
- FMNB Nasdaq
- RGNX Nasdaq
- Market Cap
- FMNB 503.3M
- RGNX 424.8M
- IPO Year
- FMNB N/A
- RGNX 2015
- Fundamental
- Price
- FMNB $13.91
- RGNX $8.34
- Analyst Decision
- FMNB Hold
- RGNX Strong Buy
- Analyst Count
- FMNB 3
- RGNX 8
- Target Price
- FMNB $15.33
- RGNX $31.75
- AVG Volume (30 Days)
- FMNB 115.8K
- RGNX 769.5K
- Earning Date
- FMNB 07-23-2025
- RGNX 07-31-2025
- Dividend Yield
- FMNB 4.86%
- RGNX N/A
- EPS Growth
- FMNB N/A
- RGNX N/A
- EPS
- FMNB 1.28
- RGNX N/A
- Revenue
- FMNB $166,505,000.00
- RGNX $156,718,000.00
- Revenue This Year
- FMNB $19.04
- RGNX $327.08
- Revenue Next Year
- FMNB $4.36
- RGNX N/A
- P/E Ratio
- FMNB $10.92
- RGNX N/A
- Revenue Growth
- FMNB N/A
- RGNX 80.70
- 52 Week Low
- FMNB $11.58
- RGNX $5.04
- 52 Week High
- FMNB $16.32
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- FMNB 56.40
- RGNX 47.68
- Support Level
- FMNB $14.01
- RGNX $8.51
- Resistance Level
- FMNB $14.77
- RGNX $9.27
- Average True Range (ATR)
- FMNB 0.27
- RGNX 0.50
- MACD
- FMNB 0.01
- RGNX 0.02
- Stochastic Oscillator
- FMNB 58.50
- RGNX 50.37
About FMNB Farmers National Banc Corp.
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.